The approval of the Amgen product marks the third biosimilar approval in the United States since the beginning of 2020.
The FDA has approved Amgen's rituximab biosimilar Riabni, which references Rituxan and is indicated for the treatment of adult patients with non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia, granulomatosis with polyangiitis, and microscopic polyangiitis. Amgen said the product would be commercialized in the United States starting in January 2021.
The approval milestone follows recent US biosimilar launches for Amgen including a trastuzumab (Kanjinti, 2019) and bevacizumab (Mvasi, 2019). The company has 10 biosimilars in total, 5 approved in the United States and 3 available in the European Union.
Riabni is a CD20-directed cytolytic antibody that has demonstrated biosimilarity to the reference product via comparative analytical, nonclinical, and clinical data. The totality of evidence included a pharmacokinetic similarity study and comparative clinical study, Amgen said.
Efficacy, pharmacokinetics (PK), pharmacodynamics (PD), safety, tolerability and immunogenicity were evaluated in patients with grade 1, 2, or 3a follicular B-cell NHL and low tumor burden. Investigators enrolled 256 patients and randomized them 1:1 to receive 375 mg/m2 intravenously of either the biosimilar or reference product, once weekly for 4 weeks, followed by dosing at weeks 12 and 20.
Amgen said the primary end point was overall response rate by week 28, which was within the prespecified margin for equivalence to Rituxan. PK, PD, safety, and immunogenicity also were equivalent, and no meaningful differences in safety or effectiveness were detected.
The pharmaceutical company said Riabni will be marketed at a discount to the reference product of 23.7% below wholesale acquisition cost (WAC), or a WAC of $716.80 per 100 mg and $3584 per 500 mg single-dose vial. These costs are 15.2% less than the WAC for the biosimilar rituximab Truxima, Amgen said.
The company added that Riabni's average sales price will be 16.7% below the current average for Rituxan.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Trastuzumab-dkst Shows Promising Results in Real-World Setting for HER2+ Breast Cancer
July 9th 2024A Brazilian real-world study found trastuzumab-dkst to be an effective and safe adjuvant therapy for HER2-positive (HER2+) breast cancer, with clinical outcomes comparable to reference trastuzumab.